Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma
The treatment and evolution of B-cell non-Hodgkin lymphoma (B-NHL) has undergone important changes in the last years with the emergence of targeted therapies, such as monoclonal antibodies, small molecules, antibody-drug conjugates, and bispecific antibodies. Nevertheless, a significant portion of p...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fb9f576e4fc64cbf847cfdf061ac8b7e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fb9f576e4fc64cbf847cfdf061ac8b7e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fb9f576e4fc64cbf847cfdf061ac8b7e2021-11-18T04:51:00ZAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma2531-137910.1016/j.htct.2021.09.003https://doaj.org/article/fb9f576e4fc64cbf847cfdf061ac8b7e2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921001371https://doaj.org/toc/2531-1379The treatment and evolution of B-cell non-Hodgkin lymphoma (B-NHL) has undergone important changes in the last years with the emergence of targeted therapies, such as monoclonal antibodies, small molecules, antibody-drug conjugates, and bispecific antibodies. Nevertheless, a significant portion of patients remains refractory or relapsed (R/R) to the new therapeutic modalities, representing thus an unmet medical need. The use of CAR-T cells for the treatment of B-NHL patients has shown to be a promising therapy with impressive results in patients with R/R disease. The expectations are as high as the imminent approval of CAR-T cell therapy in Brazil, which it is expected to impact the prognosis of R/R B-NHL. The aim of this manuscript is to offer a consensus of specialists in the field of onco-hematology and cellular therapy, working in Brazil and United States, in order to discuss and offer recommendations in the present setting of the use of CAR-T cells for patients with B-NHL.Alvaro J. AlencarAlexandre V. HirayamaDiego V. CléMarco Aurélio SalvinoGuilherme PeriniCelso ArraisOtávio BaiocchiLeonardo Carvalho PalmaIago ColturatoJorge VazRicardo ChiattoneMarcos de LimaJayr Schmidt FilhoSamir NabhanVanderson RochaRenato L. Guerino-CunhaCarlos S. ChiattoneElsevierarticleCellular therapyCAR-T cellsImmunotherapyAdoptive cellular therapyAdvanced cellular therapyNon-Hodgkin lymphomaDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S22-S29 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Cellular therapy CAR-T cells Immunotherapy Adoptive cellular therapy Advanced cellular therapy Non-Hodgkin lymphoma Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
Cellular therapy CAR-T cells Immunotherapy Adoptive cellular therapy Advanced cellular therapy Non-Hodgkin lymphoma Diseases of the blood and blood-forming organs RC633-647.5 Alvaro J. Alencar Alexandre V. Hirayama Diego V. Clé Marco Aurélio Salvino Guilherme Perini Celso Arrais Otávio Baiocchi Leonardo Carvalho Palma Iago Colturato Jorge Vaz Ricardo Chiattone Marcos de Lima Jayr Schmidt Filho Samir Nabhan Vanderson Rocha Renato L. Guerino-Cunha Carlos S. Chiattone Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma |
| description |
The treatment and evolution of B-cell non-Hodgkin lymphoma (B-NHL) has undergone important changes in the last years with the emergence of targeted therapies, such as monoclonal antibodies, small molecules, antibody-drug conjugates, and bispecific antibodies. Nevertheless, a significant portion of patients remains refractory or relapsed (R/R) to the new therapeutic modalities, representing thus an unmet medical need. The use of CAR-T cells for the treatment of B-NHL patients has shown to be a promising therapy with impressive results in patients with R/R disease. The expectations are as high as the imminent approval of CAR-T cell therapy in Brazil, which it is expected to impact the prognosis of R/R B-NHL. The aim of this manuscript is to offer a consensus of specialists in the field of onco-hematology and cellular therapy, working in Brazil and United States, in order to discuss and offer recommendations in the present setting of the use of CAR-T cells for patients with B-NHL. |
| format |
article |
| author |
Alvaro J. Alencar Alexandre V. Hirayama Diego V. Clé Marco Aurélio Salvino Guilherme Perini Celso Arrais Otávio Baiocchi Leonardo Carvalho Palma Iago Colturato Jorge Vaz Ricardo Chiattone Marcos de Lima Jayr Schmidt Filho Samir Nabhan Vanderson Rocha Renato L. Guerino-Cunha Carlos S. Chiattone |
| author_facet |
Alvaro J. Alencar Alexandre V. Hirayama Diego V. Clé Marco Aurélio Salvino Guilherme Perini Celso Arrais Otávio Baiocchi Leonardo Carvalho Palma Iago Colturato Jorge Vaz Ricardo Chiattone Marcos de Lima Jayr Schmidt Filho Samir Nabhan Vanderson Rocha Renato L. Guerino-Cunha Carlos S. Chiattone |
| author_sort |
Alvaro J. Alencar |
| title |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma |
| title_short |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma |
| title_full |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma |
| title_fullStr |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma |
| title_full_unstemmed |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma |
| title_sort |
associação brasileira de hematologia, hemoterapia e terapia celular consensus on genetically modified cells. iii: anti-cd19 car-t cell therapy for patients with non-hodgkin lymphoma |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/fb9f576e4fc64cbf847cfdf061ac8b7e |
| work_keys_str_mv |
AT alvarojalencar associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT alexandrevhirayama associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT diegovcle associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT marcoaureliosalvino associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT guilhermeperini associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT celsoarrais associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT otaviobaiocchi associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT leonardocarvalhopalma associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT iagocolturato associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT jorgevaz associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT ricardochiattone associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT marcosdelima associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT jayrschmidtfilho associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT samirnabhan associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT vandersonrocha associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT renatolguerinocunha associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma AT carlosschiattone associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsiiianticd19cartcelltherapyforpatientswithnonhodgkinlymphoma |
| _version_ |
1718425015045586944 |